Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 2716 • 2014 ACR/ARHP Annual Meeting
Development of a “Renal Crisis Prevention Card” As an Educational Tool Aimed at Improving Outcomes in High-Risk Patients with Systemic Sclerosis
Lee S. Shapiro^1,2,3, Lesley Ann Saketkoo⁴, Jessica F. Farrell^2,3,5 and Kim Fligelstone⁶, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Center, Saratoga Springs, NY, ³The Center for Rheumatology, Albany, NY, ⁴Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁶Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a devastating complication of SSc. The introduction of effective treatment with ACE inhibition (ACE-I) in 1979 dramatically reduced…
Abstract Number: 2699 • 2014 ACR/ARHP Annual Meeting
Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts
Veronika K. Jaeger¹, Andrew Aubin², Nancy Baldwin³, Kim Fligelstone⁴, Robyn Sims⁵, Joep Welling⁶, Ryan Burrill⁷, Kerri Connolly⁷, Tracy Frech⁸, Jessica K. Gordon⁹, Tanaka Ngcozana¹⁰, Monika Kowalczyk¹¹, Matthew R. Lammi¹², Ulrich A. Walker¹ and Lesley Ann Saketkoo¹³, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ²Louisiana State University School of Medicine, New Orleans, LA, ³Scleroderma Foundation - Chicago Support Group, Chicago, IL, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Scleroderma Australia, Victoria, Australia, ⁶The Dutch Patient Organization for Systemic Autoimmune Diseases, Utrecht, Netherlands, ⁷Scleroderma Foundation, Boston, MA, ⁸Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, ¹¹DIvision of Gastroenterology, Tulane University School of Medicine, New Orleans, LA, ¹²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ¹³Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: SSc is a complex, diffuse, devastating health condition of vascular injury, inflammation and fibrosis resulting in multiple organ-system derangements with high impact on…
Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Aryeh Fischer³, Jerry A. Molitor⁴ and Virginia D. Steen⁵, ¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ³Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…
Abstract Number: 1930 • 2014 ACR/ARHP Annual Meeting
The Value of Repeated Nailfold Capillaroscopy in Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands
B. de Boer¹, J. Meijs¹, J. van Aken², T.W.J. Huizinga¹, A.a. Schouffoer³ and J.K. de Vries-Bouwstra⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Spaarne Ziekenhuis, Hoofddorp, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Nailfold capillaroscopy is an important tool to differentiate primary Raynaud's phenomenon (PRP) from secondary Raynaud's phenomenon (SRP). Based on possible transition from PRP to…
Abstract Number: 1684 • 2014 ACR/ARHP Annual Meeting
Treatment of Scleroderma Associated Lung Disease with Mycophenolate Mofetil: A Community-Based Study
Audrey Bearden¹, Kent Kwasind Huston² and Judy Foxworth³, ¹Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, ²Rheumatology, The Center for Rheumatic Disease, Kansas City, MO, ³Associate Program Director & Director of Research, The University of Missouri-Kansas City, Kansas City, MO
Background/Purpose: Interstitial lung disease occurs in over 80% of patients with scleroderma. Cyclophosphamide is the only treatment proven to benefit scleroderma lung disease in a…
Abstract Number: 1694 • 2014 ACR/ARHP Annual Meeting
a Feasibility Study of Subjective and Objective Assessment of Sublingual Abnormalities in Systemic Sclerosis
Tracy M. Frech¹, John Pauling², Maureen Murtaugh³, Lee S. Shapiro⁴, Bernard Choi⁵, Ryan Farraro⁵ and Robyn T. Domsic⁶, ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²Upper Borough Walls, Royal National Hospital for Rheumatic Disease, Bath, United Kingdom, ³Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ⁴The Center for Rheumatology, Albany, NY, ⁵University of Irvine, Irvine, CA, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Sublingual frenulum abnormalities are reported in systemic sclerosis (SSc), but the exact nature and clinical relevance of such abnormalities is unknown. Laser speckle contrast…
Abstract Number: 1691 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients with Pulmonary Hypertension Have a Lower Change in End Tidal Carbon Dioxide Following Three Minutes of Step Exercise Than Systemic Sclerosis Patients without Pulmonary Hypertension: A Cross-Sectional Study
Elana J. Bernstein¹, Jessica K. Gordon², Robert F. Spiera², Wei-Ti Huang³, Evelyn M. Horn⁴ and Lisa A. Mandl², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Cardiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients with systemic sclerosis (SSc). Transthoracic echocardiogram and pulmonary function testing are standard noninvasive…
Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Claire Owen¹, Gene Ngian², Kathleen Elford², Owen Moore³, Mandy Nikpour³, Wendy Stevens³, Susanna Proudman⁴, Janet Roddy⁵, Jane Zochling⁶, Catherine Hill⁷, Peter Nash⁸, Allan Sturgess⁹ and Joanne Sahhar², ¹Rheumatology, Monash Health, Melbourne, Australia, ²Monash Health, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Sunshine Coast Rheumatology, Maroochydore, Australia, ⁹The St George Hospital, Sydney, Australia
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Svetlana I. Nihtyanova¹, Benjamin E. Schreiber², Voon H. Ong³, John G. Coghlan⁴, Athol U. Wells⁵ and Christopher P. Denton⁶, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ³Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ⁴National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, ⁵Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁶Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…
Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Elana J. Bernstein¹, Jessica K. Gordon², Wei-Ti Huang³ and Virginia D. Steen⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Yun Zhang, Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…
Abstract Number: 688 • 2013 ACR/ARHP Annual Meeting
Minimal Clinically Important Investigations In Systemic Sclerosis
Jessica Meijs¹, Anne A. Schouffoer¹, Nina Ajmone Marsan², Maarten K. Ninaber³ and Tom W.J. Huizinga¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Cardiology, Leiden University Medical Center, Leiden, Netherlands, ³Pulmonology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The optimal management of Systemic Sclerosis (SSc) is a challenge due to the complexity of early diagnosis and identification of patients who are at…
Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting
Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile
Svetlana I. Nihtyanova¹, Voon H. Ong² and Christopher P. Denton³, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ³Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…
Abstract Number: 675 • 2013 ACR/ARHP Annual Meeting
Impact Of Male Sex On Survival In Systemic Sclerosis
Haseena Hussein¹, Peter Lee², Cathy Chau³ and Sindhu R. Johnson⁴, ¹Medicine, Toronto Scleroderma Research Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ³Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) has a female predominance with a female-to-male ratio of 3:1. Sex differences have been seen in many autoimmune diseases; however, little…
Abstract Number: 680 • 2013 ACR/ARHP Annual Meeting
Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma
Cory Perugino¹, John Stephens², Colin O'Rourke³ and Soumya Chatterjee⁴, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: Scleroderma or systemic sclerosis (SSc) is an autoimmune disease characterized by microangiopathy, tissue hypoxia, and fibrosis. At least seven different autoantibodies have been identified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.